Novavax Inc (NVAX.O) released the late-stage information from a clinical study for its Novavax covid-19 vaccine in the United States on Monday, revealing that it is more than 90% efficient against COVID-19 across a number of virus types.
According to the company, Novavax expects to petition for emergency authorization in the United States and abroad in the third quarter of 2021, based on a study of over 30,000 volunteers in the United States and Mexico.
Novavax’s protein-based COVID-19 vaccine candidate was even more than 93 percent effective against even the most prevalent COVID-19 variants that scientists and health experts have been apprehensive about.
The B.1.1.7 variant, which was first spotted in the United Kingdom, became the most prevalent variant in the United States during the experiment, according to the report.
Novavax’s chief of research and development, Dr. Gregory Glenn, told Reuters that among the participants in the study were variants of COVID-19 initially discovered in Brazil, South Africa, and India.
According to Reuters report, the vaccination of the Novavax Covid-19 Vaccine was 91 percent effective among volunteers at high risk of severe infection and 100 percent efficient in avoiding moderate and severe COVID-19 cases. It worked about 70% of the time against COVID-19 variations that Novavax couldn’t find.
Dr Glen, while speaking said
The vaccination was usually well tolerated by participants, according to Novavax. Headaches, tiredness, and muscle soreness were among the mild side effects. A limited proportion of individuals reported having serious adverse effects.
According to Novavax, the company is on course to manufacture 100 million doses per month by the end of the third quarter of 2021 and 150 million doses per month by the fourth quarter of 2021.
The business, situated in Maryland, has routinely missed manufacturing deadlines and has struggled to obtain the raw materials and equipment it needs to manufacture its vaccine.